ArticleDigestive diseases and sciences2010
Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.
Article in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Review
- Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study.Digestive diseases and sciences · 2025Article
- Impact of Obesity and Metabolic Syndrome on IBD Outcomes.Digestive diseases and sciences · 2024Review
- The Relationship of Adherence to the Mediterranean Diet with Disease Activity and Quality of Life in Crohn's Disease Patients.Medicina (Kaunas, Lithuania) · 2024Article
- The Impact of Obesity on Inflammatory Bowel Disease.Biomedicines · 2023Review
- Obesity and novel management of inflammatory bowel disease.World journal of gastroenterology · 2023Review
- Obesity, a challenge in the management of inflammatory bowel diseases.Immunologic research · 2022Review
- Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.World journal of gastroenterology · 2020Article
- Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?Frontiers in medicine · 2019Review
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?World journal of gastroenterology · 2017Review
- Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study.Therapeutic drug monitoring · 2017Article
- Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study.The Korean journal of internal medicine · 2017Article
- Interaction of obesity and inflammatory bowel disease.World journal of gastroenterology · 2016Review
- The effect of body weight on the severity and clinical course of ulcerative colitis.International journal of colorectal disease · 2015Article
- Role of moxibustion in inflammatory responses during treatment of rat ulcerative colitis.World journal of gastroenterology · 2014Article
- Health care costs and their predictors of inflammatory bowel diseases in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population.Journal of gastroenterology · 2010Article
- Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
- Metabolic syndrome frequency in inflammatory bowel diseases.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
- Commented on by
Authors and funding
25 authors at 14 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a survey comprising 1,176 patients with inflammatory bowel disease (IBD) we recently showed that azathioprine (AZA) beyond 4 years is beneficial in ulcerative colitis (UC) patients and in a subset of Crohn's disease (CD) patients. Here, we show for the first time that azathioprine responsiveness depends on body mass index (BMI). The relationship is reciprocal in UC and CD, with a better outcome in UC patients with a BMI<25 and in CD patients with a BMI>25. These observations are particularly interesting considering the evolving concept of a relationship between fatty metabolism and immune regulation. Additionally, we show that CD patients, but not UC patients, respond better to AZA when it is started in clinical remission. This observation may support data favouring a "hit hard and early" regime in CD. Finally, we were able to demonstrate a decrease in the incidence of CD-related complications requiring surgery through treatment with AZA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.